METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these three metabolic research peptides.
What is AOD-9604?
AOD-9604 is a synthetic sixteen-amino-acid peptide modelled on the C-terminal lipolytic domain of human growth hormone. Its full name is Anti-Obesity Drug 9604. It was engineered to isolate hGH's fat-metabolism effects while avoiding the growth-promoting, IGF-1-elevating, and diabetogenic effects of the intact hormone [6]. It does not bind the growth hormone receptor. Non-clinical evaluation found no genotoxic or toxicological concerns after chronic administration in rodents and primates, with a very short IV half-life of approximately 3 minutes [2].
What does the peptide AOD-9604 do?
In rodent and cell models, AOD-9604 inhibits acetyl-CoA carboxylase (the rate-limiting enzyme of fatty-acid synthesis) via a membrane-derived second messenger [7], and up-regulates beta-3 adrenergic receptor expression in white adipose tissue, increasing fat oxidation and reducing body fat [4][5]. In the human obesity programme, it did not produce statistically significant weight loss versus placebo across approximately 900 subjects and up to 24-week treatment durations [3]. The rodent fat-metabolism mechanisms have not translated into a demonstrated human fat-loss effect.
Does AOD-9604 actually work?
In obese mice: yes, it reduced body fat and increased fat oxidation, and the effect required functional beta-3 adrenergic signaling [4]. In approximately 900 obese humans across roughly six oral clinical trials: no statistically significant weight loss was demonstrated versus placebo, and the development programme was discontinued [3]. Tolerability in humans was indistinguishable from placebo — the compound appeared safe in that sense — but safety is not the same as efficacy. Community reports largely reflect the clinical data: most people do not see meaningful fat reduction. This desk does not advise on use.
How does AOD-9604 work?
Two mechanisms are documented. First, the hGH C-terminal sequence (which includes the AOD-9604 region) inhibits acetyl-CoA carboxylase, reducing de novo fatty-acid synthesis via a second messenger that increases enzyme phosphorylation — an antilipogenic mechanism established in adipocyte and hepatocyte preparations in 1983 [7]. Second, chronic treatment up-regulates beta-3 adrenergic receptor expression in white adipose tissue; the sustained body-weight and fat-loss effects in mice required functional beta3-AR, while an acute fat-oxidation effect did not [4]. In humans, neither mechanism has been confirmed to produce meaningful weight loss [3].
What is tesamorelin?
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), bearing an N-terminal modification that confers resistance to the plasma enzyme DPP-IV, extending its half-life relative to native GHRH. It is 44 amino acids long. By binding the GHRH receptor on pituitary somatotrophs, it stimulates synthesis and pulsatile secretion of endogenous growth hormone [12]. It holds an FDA approval (NDA 022505, November 2010) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [9] — a specific patient population, not a general fat-loss indication.
What does tesamorelin do?
Tesamorelin stimulates the pituitary to release growth hormone in a more physiological pulsatile pattern. The resulting GH drives hepatic production of IGF-1; together GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue. In its approved indication, this produces a sustained reduction in visceral fat of roughly 18% over 52 weeks [12] and a treatment effect of -42 cm2 versus placebo in a JAMA randomized trial [10]. A 2026 meta-analysis of five RCTs confirmed reductions in VAT (-27.71 cm2), trunk fat (-1.18 kg), and hepatic fat (-4.28%), with increased lean mass (+1.42 kg) [8]. These results are all in HIV-infected adults on antiretroviral therapy.
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade and stimulating pulsatile GH secretion. GH then promotes hepatic IGF-1 synthesis, and the GH/IGF-1 combination drives lipolysis in visceral adipose tissue. In a 2-week study in 13 healthy men, tesamorelin 2 mg/day raised mean overnight GH by 0.5 ug/L (P=0.004) and IGF-1 by 181 ug/L (P<0.0001) without significantly affecting insulin-stimulated glucose uptake [11]. Because it amplifies the body's own GH axis rather than supplying exogenous GH, its profile differs from recombinant human growth hormone.
Will tesamorelin help me lose belly fat?
The controlled evidence for tesamorelin reducing visceral fat is in HIV-infected adults on antiretroviral therapy with lipodystrophy — that is the population the pivotal trials enrolled and the FDA approved it for [9][12]. Whether it reduces visceral fat in people without HIV or lipodystrophy is mechanistically plausible but has not been established in large randomized controlled trials. It is a prescription drug outside its approved indication, and research-grade material is not approved for human self-administration. This desk does not advise on use and lists no human dose.
What does the MOTS-c peptide do?
In mice and cell models, MOTS-c inhibits the folate cycle and de novo purine biosynthesis, raises AICAR, and activates AMPK — improving glucose handling and insulin sensitivity in skeletal muscle [15]. It also directly binds and activates casein kinase 2 (CK2) with tissue-specific effects on muscle glucose uptake and atrophy prevention [13]. Under metabolic stress it translocates from the mitochondrion to the nucleus to regulate gene expression through NRF2 and antioxidant-response pathways [17]. Exercise induces endogenous MOTS-c, and exogenous MOTS-c enhanced physical performance in aged mice [16]. Human efficacy has not been established in clinical trials.
What are the negative side effects of MOTS-c?
Published human safety data for exogenous MOTS-c do not exist — there are no completed human clinical trials, so adverse effects in people are unknown. The literature notes several concerns: no validated human pharmacokinetics (rodent doses cannot be extrapolated), ancestry-dependent genetic variation in response (a pro-diabetogenic mtDNA variant m.1382A>C exists), and research-chemical supply chains with no pharmaceutical-grade purity oversight [15]. Anti-doping authorities treat MOTS-c as a prohibited substance, so athletes who use it face sanctions. Without human clinical data, it is not possible to characterize a human side-effect profile from the peer-reviewed record.
Is MOTS-c legal to buy?
MOTS-c is not a DEA-controlled substance and is sold by chemical research suppliers in jurisdictions where possession of research chemicals is permitted. It is not FDA-approved for human use, and research-grade material is legally sold as a laboratory research chemical only — not as a medicine, supplement, or food product. For competitive athletes, it is a different matter: WADA and national anti-doping authorities treat MOTS-c under hormone-and-metabolic-modulator prohibition categories, and use by athletes can result in sanctions. Regulatory status varies by jurisdiction; consult applicable local law.
How often do you inject MOTS-c?
This site does not advise on human dosing, scheduling, or administration of any compound. Dosing and frequency information exists only from rodent studies, where intraperitoneal administration at 0.5-15 mg/kg/day was used in the efficacy work [16]. No peer-reviewed literature has established a human dose, frequency, or administration route. Research-grade MOTS-c is not intended for human consumption. For any health condition, consult a licensed clinician.